APA (7th ed.) Citation

Wei, J., Luo, Y., & Fu, D. (2018). Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: A meta-analysis of randomized controlled trials. OncoTargets and therapy, 11, 9049-9059. https://doi.org/10.2147/OTT.S186816

Chicago Style (17th ed.) Citation

Wei, Jinli, Yulin Luo, and Deyuan Fu. "Early and Late Outcomes of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone as a Neoadjuvant Treatment in HER2-negative Nonmetastatic Breast Cancer: A Meta-analysis of Randomized Controlled Trials." OncoTargets and Therapy 11 (2018): 9049-9059. https://doi.org/10.2147/OTT.S186816.

MLA (9th ed.) Citation

Wei, Jinli, et al. "Early and Late Outcomes of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone as a Neoadjuvant Treatment in HER2-negative Nonmetastatic Breast Cancer: A Meta-analysis of Randomized Controlled Trials." OncoTargets and Therapy, vol. 11, 2018, pp. 9049-9059, https://doi.org/10.2147/OTT.S186816.